These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 31371380)

  • 1. Impact of preleukemic mutations and their persistence on hematologic recovery after induction chemotherapy for AML.
    Murphy T; Zou J; Daher-Reyes GS; Arruda A; Gupta V; McNamara CJ; Minden MD; Schimmer AD; Sibai H; Yee KWL; Korulla M; Stockley T; Kamel-Reid S; Maze D; Tierens A; Bratman SV; Schuh AC; Chan SM
    Blood Adv; 2019 Aug; 3(15):2307-2311. PubMed ID: 31371380
    [No Abstract]   [Full Text] [Related]  

  • 2. Routine interim disease assessment in patients undergoing induction chemotherapy for acute myeloid leukemia: Can we do better?
    Campuzano-Zuluaga G; Deutsch Y; Salzberg M; Gomez A; Vargas F; Elias R; Kwon D; Goodman M; Ikpatt OF; Chapman JR; Watts J; Vega F; Swords R
    Am J Hematol; 2016 Mar; 91(3):277-82. PubMed ID: 26663264
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relation of clinical response and minimal residual disease and their prognostic impact on outcome in acute myeloid leukemia.
    Chen X; Xie H; Wood BL; Walter RB; Pagel JM; Becker PS; Sandhu VK; Abkowitz JL; Appelbaum FR; Estey EH
    J Clin Oncol; 2015 Apr; 33(11):1258-64. PubMed ID: 25732155
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutational spectrum and risk stratification of intermediate-risk acute myeloid leukemia patients based on next-generation sequencing.
    Wang B; Liu Y; Hou G; Wang L; Lv N; Xu Y; Xu Y; Wang X; Xuan Z; Jing Y; Li H; Jin X; Deng A; Wang L; Gao X; Dou L; Liang J; Chen C; Li Y; Yu L
    Oncotarget; 2016 May; 7(22):32065-78. PubMed ID: 27062340
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Partial response after induction chemotherapy has clinical relevance in acute myeloid leukaemia.
    Fleming S; Ong DM; Jackson K; Avery S; Mollee P; Marlton P; Kennedy G; Wei AH
    Br J Haematol; 2017 Apr; 177(2):328-330. PubMed ID: 27029236
    [No Abstract]   [Full Text] [Related]  

  • 6. The prognosis and durable clearance of RAS mutations in patients with acute myeloid leukemia receiving induction chemotherapy.
    Ball BJ; Hsu M; Devlin SM; Arcila M; Roshal M; Zhang Y; Famulare CA; Goldberg AD; Cai SF; Dunbar A; Epstein-Peterson Z; Menghrajani KN; Glass JL; Taylor J; Viny AD; Giralt SS; Gyurkocza B; Shaffer BC; Tamari R; Levine RL; Tallman MS; Stein EM
    Am J Hematol; 2021 May; 96(5):E171-E175. PubMed ID: 33650111
    [No Abstract]   [Full Text] [Related]  

  • 7. Minimal residual disease may be an early prognostic indicator for newly diagnosed acute myeloid leukemia patients induced by decitabine-based chemotherapy.
    Tan Y; Fu Y; Liu C; Sun J; Liu S; Lin H; Liu Q; Yang Y; Li Y; Su L; Gao S
    Hematology; 2019 Dec; 24(1):552-558. PubMed ID: 31315553
    [No Abstract]   [Full Text] [Related]  

  • 8. Clearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid Leukemia.
    Morita K; Kantarjian HM; Wang F; Yan Y; Bueso-Ramos C; Sasaki K; Issa GC; Wang S; Jorgensen J; Song X; Zhang J; Tippen S; Thornton R; Coyle M; Little L; Gumbs C; Pemmaraju N; Daver N; DiNardo CD; Konopleva M; Andreeff M; Ravandi F; Cortes JE; Kadia T; Jabbour E; Garcia-Manero G; Patel KP; Futreal PA; Takahashi K
    J Clin Oncol; 2018 Jun; 36(18):1788-1797. PubMed ID: 29702001
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination treatment of an IDH1 inhibitor with chemotherapy in IDH1 mutant acute myeloid leukemia.
    Gupta C; Kaulfuss S; Görlich K; Othman B; Chaturvedi A; Heuser M
    Ann Hematol; 2020 Jun; 99(6):1415-1417. PubMed ID: 32296913
    [No Abstract]   [Full Text] [Related]  

  • 10. Rebound thrombocytosis is associated with response in AML patients treated with venetoclax and hypomethylating agents.
    Othman TA; Mei M; Zhang J; Aldoss I; Stein A; Forman SJ; Marcucci G; Pullarkat V
    Am J Hematol; 2021 May; 96(5):E140-E143. PubMed ID: 33524204
    [No Abstract]   [Full Text] [Related]  

  • 11. Early recovery of the platelet count after decitabine-based induction chemotherapy is a prognostic marker of superior response in elderly patients with newly diagnosed acute myeloid leukaemia.
    Huang J; Zhao H; Hong M; Zhu H; Zhu Y; Lian Y; Li S; Li J; Qian S
    BMC Cancer; 2018 Dec; 18(1):1269. PubMed ID: 30567513
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monocytes-neutrophils-ratio as predictive marker for failure of first induction therapy in AML.
    Mika T; Ladigan S; Schork K; Turewicz M; Eisenacher M; Schmiegel W; Schroers R; Baraniskin A
    Blood Cells Mol Dis; 2019 Jul; 77():103-108. PubMed ID: 31029023
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Integrating resistance functions to predict response to induction chemotherapy in de novo acute myeloid leukemia.
    Chiu YC; Hsiao TH; Tsai JR; Wang LJ; Ho TC; Hsu SL; Teng CJ
    Eur J Haematol; 2019 Oct; 103(4):417-425. PubMed ID: 31356696
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PPM1D mutations appear in complete remission after exposure to chemotherapy without predicting emerging AML relapse.
    Al Hinai ASA; Grob T; Rijken M; Kavelaars FG; Zeilemaker A; Erpelinck-Verschueren CAJ; Sanders MA; Löwenberg B; Jongen-Lavrencic M; Valk PJM
    Leukemia; 2021 Sep; 35(9):2693-2697. PubMed ID: 33589749
    [No Abstract]   [Full Text] [Related]  

  • 15. Impact of ABC single nucleotide polymorphisms upon the efficacy and toxicity of induction chemotherapy in acute myeloid leukemia.
    Megías-Vericat JE; Montesinos P; Herrero MJ; Moscardó F; Bosó V; Rojas L; Martínez-Cuadrón D; Hervás D; Boluda B; García-Robles A; Rodríguez-Veiga R; Martín-Cerezuela M; Cervera J; Sendra L; Sanz J; Miguel A; Lorenzo I; Poveda JL; Sanz MÁ; Aliño SF
    Leuk Lymphoma; 2017 May; 58(5):1197-1206. PubMed ID: 27701910
    [TBL] [Abstract][Full Text] [Related]  

  • 16. AML refractory to primary induction with Ida-FLAG has a poor clinical outcome.
    Kavanagh S; Heath E; Hurren R; Gronda M; Barghout SH; Liyanage SU; Siriwardena TP; Claudio J; Zhang T; Sukhai M; Stockley TL; Kamel-Reid S; Rostom A; Lutynski A; Khalaf D; Rydlewski A; Chan SM; Gupta V; Maze D; Sibai H; Schuh AC; Yee K; Minden MD; Schimmer AD
    Leuk Res; 2018 May; 68():22-28. PubMed ID: 29518628
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of minimal residual disease in the management of acute myeloid leukemia-a case-based discussion.
    Coltoff A; Houldsworth J; Keyzner A; Renteria AS; Mascarenhas J
    Ann Hematol; 2018 Jul; 97(7):1155-1167. PubMed ID: 29704019
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gene expression profiling of acute myeloid leukemia samples from adult patients with AML-M1 and -M2 through boutique microarrays, real-time PCR and droplet digital PCR.
    Handschuh L; Kaźmierczak M; Milewski MC; Góralski M; Łuczak M; Wojtaszewska M; Uszczyńska-Ratajczak B; Lewandowski K; Komarnicki M; Figlerowicz M
    Int J Oncol; 2018 Mar; 52(3):656-678. PubMed ID: 29286103
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Complete, yet partial: the benefits of complete response with partial haematological recovery as an endpoint in acute myeloid leukaemia clinical trials.
    Shallis RM; Pollyea DA; Zeidan AM
    Lancet Haematol; 2020 Dec; 7(12):853-856. PubMed ID: 33242436
    [No Abstract]   [Full Text] [Related]  

  • 20. Impact of NPM1 mutation subtypes on treatment outcome in AML: The Lyon-University Hospital experience.
    Heiblig M; Sujobert P; Hayette S; Balsat M; Elhamri M; Salles G; Thomas X
    Leuk Res; 2019 Jan; 76():29-32. PubMed ID: 30529680
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.